Terconazole - a new broad-spectrum antifungal.
Terconazole, a new triazole ketal, is found to be highly active in vitro on a wide range of yeasts and mycelium-forming fungi. The in vitro activity depends largely on the medium used. In vitro it is a potent antifungal agent in preventing the morphogenetic transformation of the yeast into the (pseudo-)mycelium form of Candida albicans. In vivo terconazole is highly active in topical treatment of various experimental models of dermatophytosis and candidosis. It also possesses moderate oral broad-spectrum activity. No side effects were observed.
D000284:Administration, Oral; D000818:Animals; D000935:Antifungal Agents; D002177:Candidiasis / Q000188:drug therapy*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D003881:Dermatomycoses / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005658:Fungi / Q000187:drug effects*; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D051381:Rats; D011919:Rats, Inbred Strains; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology*; D014247:Trichomonas Vaginitis / Q000188:drug therapy; D014422:Turkeys; D015003:Yeasts / Q000187:drug effects
D000935:Antifungal Agents; D014230:Triazoles; C037815:terconazole